"Antipsychotic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus.
Descriptor ID |
D014150
|
MeSH Number(s) |
D27.505.696.277.950.040 D27.505.954.427.210.950.040 D27.505.954.427.700.872.331
|
Concept/Terms |
Antipsychotic Agents- Antipsychotic Agents
- Agents, Antipsychotic
- Antipsychotics
- Major Tranquilizers
- Tranquilizers, Major
- Tranquillizing Agents, Major
- Agents, Major Tranquillizing
- Major Tranquillizing Agents
- Neuroleptic Drugs
- Drugs, Neuroleptic
- Neuroleptics
- Tranquilizing Agents, Major
- Agents, Major Tranquilizing
- Major Tranquilizing Agents
- Antipsychotic Drugs
- Drugs, Antipsychotic
- Neuroleptic Agents
- Agents, Neuroleptic
Antipsychotic Effect- Antipsychotic Effect
- Effect, Antipsychotic
- Antipsychotic Effects
- Effects, Antipsychotic
|
Below are MeSH descriptors whose meaning is more general than "Antipsychotic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antipsychotic Agents".
This graph shows the total number of publications written about "Antipsychotic Agents" by people in this website by year, and whether "Antipsychotic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2019 | 0 | 1 | 1 |
2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antipsychotic Agents" by people in Profiles.
-
Clozapine prescribing barriers in the management of treatment-resistant schizophrenia: A systematic review. Medicine (Baltimore). 2021 Nov 12; 100(45):e27694.
-
A retrospective cohort study of the prevalence of anxiety and agitation in schizophrenic smokers and the unmet needs of smoking cessation programs. Medicine (Baltimore). 2019 Oct; 98(40):e17375.
-
Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial. JAMA. 2017 Jul 11; 318(2):132-145.
-
Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market? Expert Opin Investig Drugs. 2008 Jan; 17(1):61-75.
-
CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited. Pharmacogenet Genomics. 2007 May; 17(5):339-47.
-
Second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia: an observational pharmacoepidemiology study from 1988 to 2002. J Clin Psychopharmacol. 2007 Feb; 27(1):46-51.
-
Determination of Olanzapine in rat brain using liquid chromatography with coulometric detection and a rapid solid-phase extraction procedure. J Chromatogr A. 2006 Jul 28; 1122(1-2):21-7.
-
Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines. Expert Opin Pharmacother. 2006 Feb; 7(2):119-33.
-
Pharmacogenomic-guided rational therapeutic drug monitoring: conceptual framework and application platforms for atypical antipsychotics. Curr Med Chem. 2004 Feb; 11(3):297-312.
-
Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C-->A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. J Clin Psychopharmacol. 2001 Dec; 21(6):603-7.